MA35460B1 - Composés et compositions en tant qu'inhibiteurs de kinase c-kit - Google Patents

Composés et compositions en tant qu'inhibiteurs de kinase c-kit

Info

Publication number
MA35460B1
MA35460B1 MA36864A MA36864A MA35460B1 MA 35460 B1 MA35460 B1 MA 35460B1 MA 36864 A MA36864 A MA 36864A MA 36864 A MA36864 A MA 36864A MA 35460 B1 MA35460 B1 MA 35460B1
Authority
MA
Morocco
Prior art keywords
compounds
kinase inhibitors
compositions
kit kinase
kit
Prior art date
Application number
MA36864A
Other languages
English (en)
French (fr)
Inventor
Valentina Molteni
Hank Michael James Petrassi
Xiaolin Li
Xiaodong Liu
Jon Loren
Juliet Nabakka
Bao Nguyen
Vince Yeh
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of MA35460B1 publication Critical patent/MA35460B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA36864A 2011-09-01 2014-03-28 Composés et compositions en tant qu'inhibiteurs de kinase c-kit MA35460B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161530038P 2011-09-01 2011-09-01
PCT/US2012/052802 WO2013033167A1 (en) 2011-09-01 2012-08-29 Compounds and compositions as c-kit kinase inhibitors

Publications (1)

Publication Number Publication Date
MA35460B1 true MA35460B1 (fr) 2014-09-01

Family

ID=46829904

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36864A MA35460B1 (fr) 2011-09-01 2014-03-28 Composés et compositions en tant qu'inhibiteurs de kinase c-kit

Country Status (30)

Country Link
US (3) US8569283B2 (cg-RX-API-DMAC7.html)
EP (1) EP2751104B1 (cg-RX-API-DMAC7.html)
JP (1) JP6134319B2 (cg-RX-API-DMAC7.html)
KR (1) KR101962495B1 (cg-RX-API-DMAC7.html)
CN (1) CN103797011B (cg-RX-API-DMAC7.html)
AP (1) AP2014007493A0 (cg-RX-API-DMAC7.html)
AR (1) AR087753A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012302042B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014004560A2 (cg-RX-API-DMAC7.html)
CA (1) CA2845169C (cg-RX-API-DMAC7.html)
CL (1) CL2014000492A1 (cg-RX-API-DMAC7.html)
CO (1) CO6900141A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140107A (cg-RX-API-DMAC7.html)
CU (1) CU20140024A7 (cg-RX-API-DMAC7.html)
EA (1) EA026152B1 (cg-RX-API-DMAC7.html)
ES (1) ES2761332T3 (cg-RX-API-DMAC7.html)
GT (1) GT201400034A (cg-RX-API-DMAC7.html)
IL (1) IL231227A0 (cg-RX-API-DMAC7.html)
MA (1) MA35460B1 (cg-RX-API-DMAC7.html)
MX (1) MX339937B (cg-RX-API-DMAC7.html)
PE (1) PE20140909A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014500372A1 (cg-RX-API-DMAC7.html)
PL (1) PL2751104T3 (cg-RX-API-DMAC7.html)
PT (1) PT2751104T (cg-RX-API-DMAC7.html)
SG (1) SG2014014369A (cg-RX-API-DMAC7.html)
TN (1) TN2014000068A1 (cg-RX-API-DMAC7.html)
TW (1) TW201313717A (cg-RX-API-DMAC7.html)
UY (1) UY34301A (cg-RX-API-DMAC7.html)
WO (1) WO2013033167A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201401175B (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9199981B2 (en) * 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
UY34301A (es) 2011-09-01 2013-04-05 Irm Llc COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit
EP3007689B1 (en) 2013-01-10 2018-03-07 Pulmokine, Inc. Non-selective kinase inhibitors
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9925184B2 (en) 2013-10-11 2018-03-27 Pulmokine, Inc. Spray-dry formulations
US20150288928A1 (en) * 2014-04-08 2015-10-08 Sony Corporation Security camera system use of object location tracking data
CN105384738B (zh) * 2014-08-21 2017-08-29 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CN108235704B (zh) 2015-07-02 2021-10-26 爱尔兰詹森科学公司 抗细菌化合物
US10474987B2 (en) * 2015-08-05 2019-11-12 Whirlpool Corporation Object recognition system for an appliance and method for managing household inventory of consumables
WO2017214413A1 (en) * 2016-06-08 2017-12-14 Chrysalis, Inc. Imidazo[1,2-a]pyridine derivatives as histone demethylase inhibitors
MA45377A (fr) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Co Composés hétérocycliques en tant qu'agents antibacteriens
BR112018075939A2 (pt) 2016-06-16 2019-04-09 Janssen Sciences Ireland Unlimited Company compostos heterocíclicos como antibacterianos
EP3515446B1 (en) 2016-09-19 2023-12-20 Novartis AG Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
AU2017348354B2 (en) 2016-10-27 2023-06-15 Pulmokine, Inc. Combination therapy for treating pulmonary hypertension
US20180162291A1 (en) * 2016-12-12 2018-06-14 Wipro Limited System and method of dynamically adjusting field of view of an image capturing device
EP4417262A3 (en) 2017-03-01 2024-11-27 Janssen Sciences Ireland Unlimited Company Combination therapy
DK3618875T3 (da) 2017-05-02 2023-07-10 Novartis Ag Kombinationsterapi omfattende en raf-inhibitor og trametinib
AU2018358160B2 (en) 2017-11-02 2023-03-16 Abbvie Inc. Modulators of the integrated stress pathway
KR102625224B1 (ko) * 2018-10-31 2024-01-15 주식회사 큐로젠 피라졸-온 유도체를 유효성분으로 포함하는 자가면역질환의 예방, 개선 또는 치료용 조성물
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
TW202108581A (zh) * 2019-05-13 2021-03-01 瑞士商諾華公司 N-(5-(5-((1r,2s)-2氟環丙基)-1,2,4-㗁二唑-3-基)-2-甲基苯基)咪唑并[1,2-a]吡啶-3-甲醯胺之結晶型
KR102881316B1 (ko) 2019-05-13 2025-11-05 노파르티스 아게 암 치료를 위한 raf 억제제로서의 n-(3-(2-(2-하이드록시에톡시)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-2 (트리플루오로메틸)이소니코틴아미드의 새로운 결정질 형태
WO2021035788A1 (zh) 2019-08-29 2021-03-04 中国科学院合肥物质科学研究院 吡唑衍生物及其用途
ES2978573T3 (es) 2019-09-13 2024-09-16 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4181921A4 (en) 2020-07-15 2025-02-26 Third Harmonic Bio, Inc. CRYSTALLINE FORMS OF A SELECTIVE C-KIT KINASE INHIBITOR
WO2022109595A1 (en) * 2020-11-19 2022-05-27 Third Harmonic Bio, Inc. Pharmaceutical compositions of a selective c-kit kinase inhibitor and methods for making and using same
WO2022194803A1 (en) 2021-03-16 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
BR112023018655A2 (pt) 2021-03-17 2023-12-12 Janssen Sciences Ireland Unlimited Co Compostos antibacterianos
WO2022194906A1 (en) 2021-03-17 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
KR20240090864A (ko) 2021-10-28 2024-06-21 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 세균성 감염의 치료에 사용하기 위한 이미다조피리딘 아미드 및 관련 화합물
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
KR20250121029A (ko) * 2022-11-30 2025-08-11 블루프린트 메디신즈 코포레이션 두드러기 치료를 위한 야생형 c-kit 키나제 억제제로서의 n-페닐-피라졸로[1,5-a]피리딘-3-카르복사미드 유도체
WO2024124002A1 (en) * 2022-12-07 2024-06-13 Third Harmonic Bio, Inc. Compounds and compositions as c-kit kinase inhibitors
WO2024123966A1 (en) * 2022-12-07 2024-06-13 Third Harmonic Bio, Inc. Compounds and compositions as c-kit kinase inhibitors
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
WO2025072330A1 (en) * 2023-09-26 2025-04-03 Arcus Biosciences, Inc. Kit inhibitor compounds and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004001903A2 (en) 2002-06-20 2003-12-31 Beacon Looms, Inc. Knitted electrical conductor fabric
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
AU2005281299B2 (en) 2004-09-09 2012-03-15 Natco Pharma Limited Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
EP1835934A4 (en) 2004-12-23 2010-07-28 Deciphera Pharmaceuticals Llc ENZYME MODULATORS AND TREATMENTS
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
US20100048539A1 (en) * 2006-11-03 2010-02-25 Irm Llc Compounds and compositions as protein kinase inhibitors
JP6117104B2 (ja) * 2010-11-15 2017-04-19 アッヴィ・インコーポレイテッド Namptおよびrock阻害薬
US20130023751A1 (en) 2011-07-18 2013-01-24 Samuel Victor Lichtenstein Water retention monitoring
EA201490539A1 (ru) 2011-09-01 2014-06-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов c-kit киназы
UY34301A (es) 2011-09-01 2013-04-05 Irm Llc COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit
AU2012301675A1 (en) 2011-09-01 2014-03-13 Irm Llc Compounds and compositions as PDGFR kinase inhibitors
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors

Also Published As

Publication number Publication date
GT201400034A (es) 2015-02-19
JP2014525448A (ja) 2014-09-29
CO6900141A2 (es) 2014-03-20
US8569283B2 (en) 2013-10-29
KR20140075692A (ko) 2014-06-19
CN103797011A (zh) 2014-05-14
CA2845169C (en) 2022-04-19
PE20140909A1 (es) 2014-07-20
US9023839B2 (en) 2015-05-05
US20140031333A1 (en) 2014-01-30
PT2751104T (pt) 2019-12-16
US20140228347A1 (en) 2014-08-14
MX339937B (es) 2016-06-17
ES2761332T3 (es) 2020-05-19
CA2845169A1 (en) 2013-03-07
CU20140024A7 (es) 2014-04-24
UY34301A (es) 2013-04-05
EP2751104B1 (en) 2019-09-25
JP6134319B2 (ja) 2017-05-24
EA026152B1 (ru) 2017-03-31
PL2751104T3 (pl) 2020-04-30
TN2014000068A1 (en) 2015-07-01
ZA201401175B (en) 2015-01-28
US8754071B2 (en) 2014-06-17
CN103797011B (zh) 2016-03-30
PH12014500372A1 (en) 2014-04-07
EP2751104A1 (en) 2014-07-09
EA201490545A1 (ru) 2014-07-30
CL2014000492A1 (es) 2014-10-03
AP2014007493A0 (en) 2014-03-31
IL231227A0 (en) 2014-04-30
MX2014002484A (es) 2014-11-25
AR087753A1 (es) 2014-04-16
WO2013033167A1 (en) 2013-03-07
AU2012302042A1 (en) 2014-04-17
SG2014014369A (en) 2014-09-26
US20130059832A1 (en) 2013-03-07
BR112014004560A2 (pt) 2017-04-04
AU2012302042B2 (en) 2016-03-31
TW201313717A (zh) 2013-04-01
CR20140107A (es) 2014-05-02
KR101962495B1 (ko) 2019-03-26

Similar Documents

Publication Publication Date Title
MA35460B1 (fr) Composés et compositions en tant qu'inhibiteurs de kinase c-kit
MA34969B1 (fr) Composes et compositions en tant qu inibiteurs de trk
MA35459B1 (fr) Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit
MA34948B1 (fr) Composes et procedes de modulation de kinase, et leurs indications
MA47043A1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
MA40240A (fr) Composés hétéroaryle d'inhibition de la kinase
MA40290A1 (fr) Agents immunorégulateurs
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MA31167B1 (fr) Inhibiteurs de l'activite de akt
MA41179A (fr) Composés inhibiteurs de parg
MA30772B1 (fr) Composes et compositions utilises en tant qu'inhibiteurs de proteine kinase
TN2012000073A1 (fr) Derives des l-(piperidine-4-yl) pyrazole servant de modulateurs de gpr119
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MA34474B1 (fr) Agonistes de gpr40
MX2009008099A (es) Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
MA32729B1 (fr) Derives d'acide 1-amino-2-cyclobutylethylboronique
MA38076A1 (fr) Dérivés d'oxazolidin-2-one-pyrimidine
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
BR112014003963A2 (pt) compostos e composições como inibidores de quinase c-kit
MA38810B1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MX2009011952A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
BR112014004319A2 (pt) compostos e composições como inibidores de c-kit cinase
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires